Jonathan Katz, MD
Neurology · San Francisco, CANPI 1457372823
Payments from drug & device makers
Across 460 payments — averaging $3670.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$490K
- UCB SA$256K
- Genentech, Inc.$160K
- Sanofi$148K
- Grifols USA, LLC$123K
- PTC Therapeutics, Inc.$110K
- plus $401K from 28 others
Across 1 payment — averaging $2796.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$3K
What the payments were for
- Consulting fees$190,43765%
- Speaking & faculty fees$57,90320%
- Travel & lodging$36,43812%
- Food & beverage$8,8983%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Gamunex-C$115,746
- Radicava$25,951
- SOLIRIS$20,191
- NOVAVAX COVID-19 VACCINE, ADJUVANTED$10,500
- Xembify$9,042
- VYVGART$7,789
- SPINRAZA$7,115
- Radicava ORS$5,949
- Hizentra$4,587
- GAMMAGARD LIQUID$3,578
- UPLIZNA$3,438
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$1,480
- Tiglutik$483
- RELYVRIO$140
- TEGSEDI$119
How this compares
$1,688,520 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 150 | $2,101,781 |
| ActharCorticotropin | 12 | $903,502 |
| EvrysdiRisdiplam | 25 | $788,937 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 57 | $615,297 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 31 | $554,776 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 68 | $471,257 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 24 | $298,638 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 16 | $128,105 |
| Riluzole | 127 | $23,966 |
| Azathioprine | 43 | $12,763 |
| Mycophenolate Mofetil | 43 | $3,507 |
| Gabapentin | 121 | $1,996 |
| Atropine Sulfate | 14 | $1,499 |
| Levetiracetam | 21 | $1,131 |
| Pyridostigmine Bromide | 17 | $1,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $5,050 | $903,50212 claims |
| Grifols USA, LLCGamunex-C | $123,254 | $615,29757 claims |
| CSL BehringPrivigen | $4,734 | $554,77631 claims |
| Amylyx Pharmaceuticals, Inc.Relyvrio | $29,099 | $298,63824 claims |
| PfizerOctagam | $1,611 | $128,10516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in San Francisco
- Bruce CreeSan Francisco$8M
- Stanley PrusinerSan Francisco$6.5M
- Adam BoxerSan Francisco$5.5M
- Jennifer ClarkeSan Francisco$5.1M
- Nancy Ann Oberheim BushSan Francisco$4.6M
- Emmanuelle WaubantSan Francisco$3M
- Jill OstremSan Francisco$2M
- William JagustSan Francisco$2M
- Gil RabinoviciSan Francisco$1.9M
- Julio Rojas-MartinezSan Francisco$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.